- Home
- PMCB vs MBIO Comparison
PMCB vs MBIO Comparison
Compare PMCB & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PMCB
- MBIO
- Stock Information
- Founded
- PMCB 1996
- MBIO 2015
- Country
- PMCB United States
- MBIO United States
- Employees
- PMCB N/A
- MBIO N/A
- Industry
- PMCB Biotechnology: Biological Products (No Diagnostic Substances)
- MBIO Biotechnology: Pharmaceutical Preparations
- Sector
- PMCB Health Care
- MBIO Health Care
- Exchange
- PMCB Nasdaq
- MBIO Nasdaq
- Market Cap
- PMCB 5.8M
- MBIO 4.7M
- IPO Year
- PMCB N/A
- MBIO N/A
- Fundamental
- Price
- PMCB $0.90
- MBIO $1.77
- Analyst Decision
- PMCB
- MBIO
- Analyst Count
- PMCB 0
- MBIO 0
- Target Price
- PMCB N/A
- MBIO N/A
- AVG Volume (30 Days)
- PMCB 38.8K
- MBIO 226.9K
- Earning Date
- PMCB 08-11-2025
- MBIO 08-08-2025
- Dividend Yield
- PMCB N/A
- MBIO N/A
- EPS Growth
- PMCB N/A
- MBIO N/A
- EPS
- PMCB 3.19
- MBIO N/A
- Revenue
- PMCB N/A
- MBIO N/A
- Revenue This Year
- PMCB N/A
- MBIO N/A
- Revenue Next Year
- PMCB N/A
- MBIO N/A
- P/E Ratio
- PMCB $0.28
- MBIO N/A
- Revenue Growth
- PMCB N/A
- MBIO N/A
- 52 Week Low
- PMCB $0.80
- MBIO $0.89
- 52 Week High
- PMCB $2.42
- MBIO $21.95
- Technical
- Relative Strength Index (RSI)
- PMCB 41.85
- MBIO 50.46
- Support Level
- PMCB $0.84
- MBIO $1.41
- Resistance Level
- PMCB $0.95
- MBIO $1.88
- Average True Range (ATR)
- PMCB 0.07
- MBIO 0.17
- MACD
- PMCB -0.00
- MBIO 0.01
- Stochastic Oscillator
- PMCB 39.96
- MBIO 68.52
About PMCB PharmaCyte Biotech Inc.
PharmaCyte Biotech Inc is a clinical-stage biotechnology company. The company is focused on developing and preparing to commercialize cellular therapies for cancer and diabetes based on a proprietary cellulose-based live cell encapsulation technology called Cell-in-a-Box. The Cell-in-a-Box technology is intended to be used as a platform upon which therapies for several types of cancer, including inoperable pancreatic cancer, and diabetes will be developed. The company is developing therapies for the pancreas and other solid cancerous tumors involving the encapsulation of live cells placed in the body to enable the delivery of cancer-killing drugs at the source of cancer.
About MBIO Mustang Bio Inc.
Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs in cell and gene therapy into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.